Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Influenza, Human × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 39 Carcinoma, Non-Small-Cell Lung 8 Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Renal Cell 5 Skin Neoplasms 4 Prostatic Neoplasms 4 Carcinoma, Hepatocellular 4 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Glioblastoma 3 Breast Neoplasms 3 Advanced Cancer 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myeloproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Very High Risk Prostate Carcinoma 1 Urinary Bladder Neoplasms 1

Interventions

Influenza Vaccines 2 Nivolumab 1 Ipilimumab 1 Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Diphtheria-Tetanus Vaccine 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05116917 2024-05-28

INFLUENCE

Herlev Hospital

Phase 2 Terminated

Gastrointestinal

Influenza, Human, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡